ATOS Stock Summary and Trading Ideas (Atossa Therapeutics | NASDAQ:ATOS)

Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary innovative medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.

Atossa Therapeutics trades on the NASDAQ stock market under the symbol ATOS.

As of December 20, 2024, ATOS stock price declined to $0.96 with 1,029,089 million shares trading.

ATOS has a beta of 2.28, meaning it tends to be more sensitive to market movements. ATOS has a correlation of 0.17 to the broad based SPY ETF.

ATOS has a market cap of $121.19 million. This is considered a Micro Cap stock.

In the last 3 years, ATOS traded as high as $2.31 and as low as $.50.

The top ETF exchange traded funds that ATOS belongs to (by Net Assets): VTI, IWM, VXF, IWN, VTWO.

ATOS has outperformed the market in the last year with a return of +32.4%, while the SPY ETF gained +27.8%. However, in the most recent history, ATOS shares have underperformed the stock market with its stock returning -34.0% in the last 3 month period and -21.0% for the last 2 week period, while SPY has returned +4.4% and -2.4%, respectively.

ATOS support price is $.94 and resistance is $1.02 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ATOS shares will trade within this expected range on the day.